HRP20110370T1 - Uporaba agomelatina za dobivanje lijeka u cilju liječenja smith-magenisovog sindroma - Google Patents
Uporaba agomelatina za dobivanje lijeka u cilju liječenja smith-magenisovog sindroma Download PDFInfo
- Publication number
- HRP20110370T1 HRP20110370T1 HR20110370T HRP20110370T HRP20110370T1 HR P20110370 T1 HRP20110370 T1 HR P20110370T1 HR 20110370 T HR20110370 T HR 20110370T HR P20110370 T HRP20110370 T HR P20110370T HR P20110370 T1 HRP20110370 T1 HR P20110370T1
- Authority
- HR
- Croatia
- Prior art keywords
- agomelatine
- smith
- magenis syndrome
- acebutolol
- pharmaceutically acceptable
- Prior art date
Links
- YJYPHIXNFHFHND-UHFFFAOYSA-N agomelatine Chemical compound C1=CC=C(CCNC(C)=O)C2=CC(OC)=CC=C21 YJYPHIXNFHFHND-UHFFFAOYSA-N 0.000 title claims abstract 11
- 229960002629 agomelatine Drugs 0.000 title claims abstract 8
- 201000001388 Smith-Magenis syndrome Diseases 0.000 title claims abstract 6
- 229940079593 drug Drugs 0.000 title claims abstract 3
- 239000003814 drug Substances 0.000 title claims abstract 3
- GOEMGAFJFRBGGG-UHFFFAOYSA-N acebutolol Chemical compound CCCC(=O)NC1=CC=C(OCC(O)CNC(C)C)C(C(C)=O)=C1 GOEMGAFJFRBGGG-UHFFFAOYSA-N 0.000 claims abstract 5
- 229960002122 acebutolol Drugs 0.000 claims abstract 5
- 239000002253 acid Substances 0.000 claims abstract 4
- 150000004677 hydrates Chemical class 0.000 claims abstract 4
- 150000003839 salts Chemical class 0.000 claims abstract 4
- 239000000825 pharmaceutical preparation Substances 0.000 claims 2
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
Landscapes
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Epidemiology (AREA)
- Anesthesiology (AREA)
- Endocrinology (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Psychology (AREA)
- Physical Education & Sports Medicine (AREA)
- Diabetes (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Connection Of Batteries Or Terminals (AREA)
- General Preparation And Processing Of Foods (AREA)
- Primary Cells (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Uporaba agomelatina, ili N-[2-(7-metoksi-1-naftil)etil]acetamida ili jednog od njegovih hidrata, kristalnih oblika ili adicijskih soli s farmaceutski prihvatljivom kiselinom ili bazom u kombinaciji s acebutololom, naznačena time, da se koristi za dobivanje lijeka za liječenje Smith-Magenisovog sindroma. Patent sadrži još 5 patentnih zahtjeva.
Claims (6)
1. Uporaba agomelatina, ili N-[2-(7-metoksi-1-naftil)etil]acetamida ili jednog od njegovih hidrata, kristalnih oblika ili adicijskih soli s farmaceutski prihvatljivom kiselinom ili bazom u kombinaciji s acebutololom, naznačena time, da se koristi za dobivanje lijeka za liječenje Smith-Magenisovog sindroma.
2. Uporaba u skladu s patentnim zahtjevom 1, naznačena time, da se agomelatin dobiva u kristalnom obliku II.
3. Farmaceutski pripravci koji sadrže agomelatin ili jedan od njegovih hidrata, kristalnih oblika ili adicijskih soli s farmaceutski prihvatljivom kiselinom ili bazom u kombinaciji s acebutololom, s jednim ili više farmaceutski prihvatljivih ekscipijensa, naznačeni time, da se koriste u liječenju Smith-Magenisovog sindroma.
4. Farmaceutski pripravak u skladu s patentnim zahtjevom 3, naznačen time, da se agomelatin dobiva u kristalnom obliku II.
5. Agomelatin, ili N-[2-(7-metoksi-1-naftil)etil]acetamid ili jedan od njegovih hidrata, kristalnih oblika ili adicijskih soli s farmaceutski prihvatljivom kiselinom ili bazom u kombinaciji s acebutololom, naznačen time, da se koristi u liječenju Smith-Magenisovog sindroma.
6. Kristalni oblik II agomelatina u kombinaciji s acebutololom, naznačen time, da se koristi u liječenju Smith-Magenisovog sindroma.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FR0610296A FR2908995B1 (fr) | 2006-11-24 | 2006-11-24 | Utilisation de l'agomelatine pour l'obtention de medicaments destines au traitement du syndrome de smith magenis |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20110370T1 true HRP20110370T1 (hr) | 2011-06-30 |
Family
ID=38229648
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HR20110370T HRP20110370T1 (hr) | 2006-11-24 | 2011-05-18 | Uporaba agomelatina za dobivanje lijeka u cilju liječenja smith-magenisovog sindroma |
Country Status (38)
| Country | Link |
|---|---|
| US (1) | US20080132577A1 (hr) |
| EP (1) | EP1929999B1 (hr) |
| JP (1) | JP2008127395A (hr) |
| KR (2) | KR20080047299A (hr) |
| CN (1) | CN101194901A (hr) |
| AR (1) | AR063896A1 (hr) |
| AT (1) | ATE501717T1 (hr) |
| AU (1) | AU2007234614B2 (hr) |
| BR (1) | BRPI0704453A2 (hr) |
| CA (1) | CA2610638C (hr) |
| CL (1) | CL2007003396A1 (hr) |
| CY (1) | CY1111430T1 (hr) |
| DE (1) | DE602007013166D1 (hr) |
| DK (1) | DK1929999T3 (hr) |
| EA (1) | EA013471B1 (hr) |
| ES (1) | ES2363252T3 (hr) |
| FR (1) | FR2908995B1 (hr) |
| GE (1) | GEP20094746B (hr) |
| HR (1) | HRP20110370T1 (hr) |
| JO (1) | JO2656B1 (hr) |
| MA (1) | MA29523B1 (hr) |
| ME (1) | ME01959B (hr) |
| MX (1) | MX2007014199A (hr) |
| MY (1) | MY145139A (hr) |
| NO (1) | NO338951B1 (hr) |
| NZ (1) | NZ563684A (hr) |
| PE (1) | PE20081347A1 (hr) |
| PL (1) | PL1929999T3 (hr) |
| PT (1) | PT1929999E (hr) |
| RS (1) | RS51676B (hr) |
| SA (1) | SA07280635B1 (hr) |
| SG (1) | SG143203A1 (hr) |
| SI (1) | SI1929999T1 (hr) |
| TW (1) | TWI370735B (hr) |
| UA (1) | UA94042C2 (hr) |
| UY (1) | UY30704A1 (hr) |
| WO (1) | WO2008071870A2 (hr) |
| ZA (1) | ZA200710103B (hr) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PH12012000132A1 (en) * | 2011-06-09 | 2014-10-20 | Servier Lab | New co-crystals of agomelatine, a process for their preparation and pharmaceutical compositions containing them |
| FR2978916B1 (fr) * | 2011-08-10 | 2013-07-26 | Servier Lab | Composition pharmaceutique solide pour administration buccale d'agomelatine |
| EP2810647A1 (en) | 2013-06-06 | 2014-12-10 | Zentiva, a.s. | Pharmaceutical formulations comprising agomelatine in the form of agomelatine co-crystal with an organic acid |
| EP2810656B1 (en) | 2013-06-06 | 2017-08-02 | Zentiva, a.s. | Agomelatine formulations comprising agomelatine in the form of co-crystals |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US1564202A (en) * | 1924-05-20 | 1925-12-08 | Christensen Jens Herman | Method of producing water-insoluble multicolored screens |
| FR2658818B1 (fr) | 1990-02-27 | 1993-12-31 | Adir Cie | Nouveaux derives a structure naphtalenique, leur procede de preparation et les compositions pharmaceutiques qui les contiennent. |
| FR2866335B1 (fr) * | 2004-02-13 | 2006-05-26 | Servier Lab | Nouveau procede de synthese de l'agomelatine |
-
2006
- 2006-11-24 FR FR0610296A patent/FR2908995B1/fr not_active Expired - Fee Related
-
2007
- 2007-01-01 ZA ZA200710103A patent/ZA200710103B/en unknown
- 2007-11-07 PE PE2007001528A patent/PE20081347A1/es not_active Application Discontinuation
- 2007-11-08 UY UY30704A patent/UY30704A1/es not_active Application Discontinuation
- 2007-11-13 MY MYPI20071976A patent/MY145139A/en unknown
- 2007-11-13 MX MX2007014199A patent/MX2007014199A/es active IP Right Grant
- 2007-11-19 MA MA30379A patent/MA29523B1/fr unknown
- 2007-11-21 US US11/986,501 patent/US20080132577A1/en not_active Abandoned
- 2007-11-22 CL CL200703396A patent/CL2007003396A1/es unknown
- 2007-11-22 AU AU2007234614A patent/AU2007234614B2/en not_active Ceased
- 2007-11-22 JO JO2007487A patent/JO2656B1/en active
- 2007-11-22 JP JP2007302457A patent/JP2008127395A/ja active Pending
- 2007-11-22 GE GEAP200710391A patent/GEP20094746B/en unknown
- 2007-11-22 AR ARP070105184A patent/AR063896A1/es unknown
- 2007-11-23 BR BRPI0704453-4A patent/BRPI0704453A2/pt not_active Application Discontinuation
- 2007-11-23 CA CA2610638A patent/CA2610638C/fr not_active Expired - Fee Related
- 2007-11-23 UA UAA200713021A patent/UA94042C2/ru unknown
- 2007-11-23 ME MEP-2011-219A patent/ME01959B/me unknown
- 2007-11-23 EP EP07291391A patent/EP1929999B1/fr active Active
- 2007-11-23 SI SI200730595T patent/SI1929999T1/sl unknown
- 2007-11-23 DK DK07291391.6T patent/DK1929999T3/da active
- 2007-11-23 KR KR1020070120251A patent/KR20080047299A/ko not_active Application Discontinuation
- 2007-11-23 NO NO20075989A patent/NO338951B1/no not_active IP Right Cessation
- 2007-11-23 TW TW096144583A patent/TWI370735B/zh not_active IP Right Cessation
- 2007-11-23 CN CNA2007103061420A patent/CN101194901A/zh active Pending
- 2007-11-23 SG SG200718042-5A patent/SG143203A1/en unknown
- 2007-11-23 WO PCT/FR2007/001926 patent/WO2008071870A2/fr active Application Filing
- 2007-11-23 EA EA200702318A patent/EA013471B1/ru not_active IP Right Cessation
- 2007-11-23 NZ NZ563684A patent/NZ563684A/en not_active IP Right Cessation
- 2007-11-23 ES ES07291391T patent/ES2363252T3/es active Active
- 2007-11-23 AT AT07291391T patent/ATE501717T1/de active
- 2007-11-23 RS RS20110157A patent/RS51676B/en unknown
- 2007-11-23 PL PL07291391T patent/PL1929999T3/pl unknown
- 2007-11-23 PT PT07291391T patent/PT1929999E/pt unknown
- 2007-11-23 DE DE602007013166T patent/DE602007013166D1/de active Active
- 2007-11-24 SA SA07280635A patent/SA07280635B1/ar unknown
-
2011
- 2011-04-27 CY CY20111100416T patent/CY1111430T1/el unknown
- 2011-05-18 HR HR20110370T patent/HRP20110370T1/hr unknown
- 2011-07-06 KR KR1020110066825A patent/KR20110086673A/ko not_active Application Discontinuation
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20100577T1 (hr) | Uporaba agomelatina za dobivanje lijeka s ciljem liječenja općeg poremećaja anksioznosti | |
| AR056063A1 (es) | Utilizacion de la agomelatina para la obtencion de medicamentos destinados al tratamiento de trastornos del sueno en el paciente deprimido | |
| CY1124432T1 (el) | Φαρμακευτικες συνθεσεις που αποτελουν ν-(3,5-διμεθοδυφαινυλ)-ν'-(1-μεθυλαιθυλ)-ν-[3-(1--μεθυλ-1η-πυραζολ-4-υλ)κινοοξαλιν-6-υλ]αιθανο-1,2-διαμινη | |
| BRPI1006812A2 (pt) | sal de malato de n-(4-{[6,7-bis(metiloxi)quinolin-4-il]fenil)-n-(4-fluorofenil)ciclopropane-1,1-dicarboxamida | |
| RS54707B1 (en) | TREATMENT OF CROWN LAKVINIMOD DISEASE | |
| JP2014530220A5 (hr) | ||
| AR060019A1 (es) | Composicion farmaceutica, producto y metodo de tratamiento para un trastorno cognitivo y usos de un inhibidor de acetilcolinesterasa y un antagonista de 5- ht6 en la fabricacion de un medicamento para el tratamiento de un trastorno cognitivo | |
| EA202091597A1 (ru) | Способы и композиции для лечения апноэ сна | |
| HRP20110370T1 (hr) | Uporaba agomelatina za dobivanje lijeka u cilju liječenja smith-magenisovog sindroma | |
| CL2009000980A1 (es) | Uso de (s)-n-(2-(1,6,8-tetrahidro-2h-inden[5,4-b]furan-8-il)etil]propionamida en combinacion con una o más drogas seleccionadas de un grupo definido para preparar un medicamento útil para la prevencion o tratamiento de la depresión o desórdenes de ansiedad (divisional de la solicitud 749-2006). | |
| HRP20180537T1 (hr) | Uporaba agomelatina za pripravu lijekova za liječenje opsesivno-kompulzivnog poremećaja (ocd) | |
| HRP20110083T1 (hr) | Uporaba agomelatina u proizvodnji lijeka za liječenje bipolarnih poremećaja | |
| HRP20100680T1 (hr) | Upotreba agomelatina za dobivanje lijeka u cilju lijecenja periventrikularne leukomalacije | |
| RU2010146309A (ru) | Фармацевтическая композиция для лечения фибромиалгии | |
| EA201400484A1 (ru) | Трансдермальное средство для лечения и профилактики болезней суставов и мягких тканей | |
| RU2013114246A (ru) | Комбинация hdac ингибиторов с лекарственными средствами против тромбоцитопении | |
| RU2015121239A (ru) | Комбинированная фармацевтическая композиция для лечения болевых синдромов | |
| Karateev et al. | Topical NSAIDS forms: Efficiency and safety | |
| AR081007A1 (es) | Combinacion farmaceutica caracterizada porque comprende ibuprofeno y l-arginina | |
| MX2022012693A (es) | Composicion que comprende metilfolato. | |
| TH85272A (th) | การใช้อะโกเมลาทีนในการได้มาเป็นยาเวชภัณฑ์ที่มุ่งหมายเพื่อการบำบัดความผิดปกติของโรคไบโพลาร์ | |
| RU2009142700A (ru) | Противовоспалительное и противоаллергическое лекарственное средство и фармацевтическая композиция на его основе | |
| MX2021004412A (es) | Cocristales que comprenden levotiroxina y un acido dicarboxilico. | |
| UA123399U (uk) | Фармацевтична композиція холіну альфосцерату у лікарській формі для орального застосування | |
| EA201000810A1 (ru) | Фармацевтическая композиция |